FDA approves skin cancer drug

Oct 13, 2006

The U.S. Food and Drug Administration approved a new drug to treat a rare, slow-growing skin cancer.

The FDA approved Zolinza capsules for the treatment of cutaneous T-cell lymphomalymphoma, a lymphoma that affects the skin. The FDA, in a news release, said the drug was approved to use when the disease worsens, is persistent or returns after treatment with other drugs.

About 3 in 1 million people, mainly middle-aged men, are diagnosed with CTCL each year, the FDA said.

The FDA said it approved Zolinza as part of its Orphan Drug program, which offers companies financial incentives to develop medicines for diseases and conditions affecting fewer than 200,000 people in the United States a year.

Zolinza is manufactured by Pantheon Inc. for Merck & Co. Inc., the FDA said.

Copyright 2006 by United Press International

Explore further: Prescription drug monitoring programs offer multiple benefits

Related Stories

VCs bet big on Silicon Valley biotech

May 28, 2015

Companies searching for cures for cancer and testing treatments for crippling genetic diseases are capturing the interest of venture capitalists - and their money - more than at any time in the last seven years.

Why Americans can't buy some of the best sunscreens

May 27, 2015

With summer nearly here, U.S. consumers might think they have an abundance of sunscreen products to choose from. But across the Atlantic, Europeans will be slathering on formulations that manufacturers say provide better ...

Recommended for you

FDA clears drug for leading form of cystic fibrosis

Jul 02, 2015

Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung infections and early death. But it will ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.